Avidity Biosciences, Inc. RNA
Institutional shares held
107 Million
224K
calls
161K
puts
Total value of holdings
$3.33B
$6.94M
calls
$5.01M
puts
Market Cap
$1.66B
52,127,000
Shares Out.
Institutional ownership
205.46%
# of Institutions
255
We take great care to ensure that the data presented and summarized in this overview for Avidity Biosciences, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding RNA
View all-
Price T Rowe Associates Inc Baltimore, MD10.6MShares$338 Million0.06% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.23MShares$294 Million0.01% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$274 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY8.13MShares$259 Million5.95% of portfolio
-
Wellington Management Group LLP Boston, MA7.03MShares$224 Million0.06% of portfolio
-
Avoro Capital Advisors LLC New York, NY6.88MShares$219 Million4.75% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.3MShares$200 Million4.04% of portfolio
-
Janus Henderson Group PLC London, X04.9MShares$156 Million0.12% of portfolio
-
State Street Corp Boston, MA4.71MShares$150 Million0.01% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.08MShares$98 Million0.26% of portfolio
Latest Institutional Activity in RNA
Top Purchases
Top Sells
About RNA
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Insider Transactions at RNA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 18
2024
|
Teresa Mc Carthy Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
11,151
-11.86%
|
$356,832
$32.66 P/Share
|
|
Dec 18
2024
|
Sarah Boyce President and CEO |
SELL
Open market or private sale
|
Direct |
31,855
-10.72%
|
$1,019,360
$32.66 P/Share
|
|
Dec 18
2024
|
Michael F Mac Lean Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
11,151
-11.85%
|
$356,832
$32.66 P/Share
|
|
Dec 18
2024
|
W. Michael Flanagan CSTO |
SELL
Open market or private sale
|
Direct |
12,742
-14.92%
|
$407,744
$32.66 P/Share
|
|
Dec 16
2024
|
Teresa Mc Carthy Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
25,000
-21.01%
|
$825,000
$33.26 P/Share
|
|
Dec 16
2024
|
Teresa Mc Carthy Chief Human Resources Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+17.36%
|
$350,000
$14.22 P/Share
|
|
Dec 11
2024
|
W. Michael Flanagan CSTO |
SELL
Open market or private sale
|
Direct |
24,000
-21.94%
|
$840,000
$35.77 P/Share
|
|
Dec 11
2024
|
W. Michael Flanagan CSTO |
BUY
Exercise of conversion of derivative security
|
Direct |
24,000
+17.99%
|
$528,000
$22.47 P/Share
|
|
Nov 19
2024
|
Arthur A Levin Director |
SELL
Open market or private sale
|
Direct |
3,323
-18.31%
|
$139,566
$42.12 P/Share
|
|
Nov 19
2024
|
Arthur A Levin Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,323
+15.47%
|
$3,323
$1.24 P/Share
|
|
Nov 18
2024
|
Teresa Mc Carthy Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
25,000
-21.01%
|
$1,025,000
$41.14 P/Share
|
|
Nov 18
2024
|
Teresa Mc Carthy Chief Human Resources Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+17.36%
|
$350,000
$14.22 P/Share
|
|
Nov 06
2024
|
Michael F Mac Lean Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
106,319
-25.41%
|
$4,784,355
$45.63 P/Share
|
|
Nov 06
2024
|
Michael F Mac Lean Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
79,057
+20.21%
|
$553,399
$7.7 P/Share
|
|
Oct 21
2024
|
Arthur A Levin Director |
SELL
Open market or private sale
|
Direct |
5,000
-25.21%
|
$230,000
$46.63 P/Share
|
|
Oct 21
2024
|
Arthur A Levin Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+20.14%
|
$5,000
$1.24 P/Share
|
|
Oct 16
2024
|
Teresa Mc Carthy Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
25,000
-21.01%
|
$1,200,000
$48.52 P/Share
|
|
Oct 16
2024
|
Teresa Mc Carthy Chief Human Resources Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+17.36%
|
$350,000
$14.22 P/Share
|
|
Oct 07
2024
|
Tamar Thompson Director |
SELL
Open market or private sale
|
Direct |
30,000
-100.0%
|
$1,320,000
$44.98 P/Share
|
|
Oct 07
2024
|
Tamar Thompson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+50.0%
|
$810,000
$27.63 P/Share
|
Last 12 Months Summary
Buy / Acquisition
2.03M
Shares
From
12
Insiders
| Grant, award, or other acquisition | 697K shares |
|---|---|
| Exercise of conversion of derivative security | 1.32M shares |
| Bona fide gift | 22.5K shares |
Sell / Disposition
1.73M
Shares
From
7
Insiders
| Open market or private sale | 1.71M shares |
|---|---|
| Bona fide gift | 22.5K shares |